Clean Vision Corp — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Clean Vision Corp filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $231.0K | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | $257.4K | Apr 15, 2025 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $219.6K | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | $162.8K | Apr 15, 2025 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($14.00M) | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | ($14.27M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($5.90M) | Aug 19, 2024 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($7.31M) | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | ($8.67M) | Apr 15, 2025 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $334.6K | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | $244.7K | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $35.5K | Aug 19, 2024 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $1.07M | Aug 19, 2024 |
| FY2023 | Dec 31, 2022 | $849.5K | Aug 19, 2024 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($4.87M) | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | ($4.70M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($2.03M) | Aug 19, 2024 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $13.07M | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | $10.59M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $377.2K | Aug 19, 2024 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $24.97M | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | $13.03M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $1.95M | Aug 19, 2024 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($11.90M) | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | ($4.24M) | Apr 15, 2025 |
| FY2024 | Dec 31, 2022 | ($3.38M) | Apr 15, 2025 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $4.85M | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | $4.85M | Apr 15, 2025 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($48.84M) | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | ($34.83M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($19.08M) | Aug 19, 2024 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $1.75M | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | $1.75M | Apr 15, 2025 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 0 | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | 0 | Apr 15, 2025 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 0 | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | 0 | Apr 15, 2025 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 807.61M | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | 682.46M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | 402.20M | Apr 16, 2024 |